IRAK-1/4 inhibitor   Click here for help

GtoPdb Ligand ID: 5990

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This is compound 46 in [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 102.53
Molecular weight 395.16
XLogP 2.43
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(c1cccc(c1)[N+](=O)[O-])Nc1nc2c(n1CCN1CCOCC1)cccc2
Isomeric SMILES O=C(c1cccc(c1)[N+](=O)[O-])Nc1nc2c(n1CCN1CCOCC1)cccc2
InChI InChI=1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Nat Biotechnol, 29 (11): 1039-45. [PMID:22037377]
2. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013)
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Biochem J, 451 (2): 313-28. [PMID:23398362]
3. Powers JP, Li S, Jaen JC, Liu J, Walker NP, Wang Z, Wesche H. (2006)
Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
Bioorg Med Chem Lett, 16 (11): 2842-5. [PMID:16563752]